Search Results - "Freston, James"

Liver Complications Following Treatment of Hematologic Malignancy With Anti‐CD22‐Calicheamicin (Inotuzumab Ozogamicin) by McDonald, George B., Freston, James W., Boyer, James L., DeLeve, Laurie D.

“…Treatment of hematological malignancy with antibody‐drug conjugates (ADCs) may cause liver injury. ADCs deliver a toxic moiety into antigen‐expressing tumor…”
Get full text

Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials by Alpers, David H., Lewis, James H., Hunt, Christine M., Freston, James W., Torres, Vicente E., Li, Hui, Wang, Wenchyi, Hoke, Molly E., Roth, Sharin E., Westcott-Baker, Lucas, Estilo, Alvin

“…Tolvaptan is associated with risk of drug-induced liver injury when used to treat autosomal dominant polycystic kidney disease (ADPKD). After this risk was…”
Get full text

Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study by Beachler, Daniel C, de Luise, Cynthia, Jamal-Allial, Aziza, Yin, Ruihua, Taylor, Devon H, Suzuki, Ayako, Lewis, James H, Freston, James W, Lanes, Stephan

“…There is limited real-world safety information on palbociclib for treatment of advanced stage HR+/HER2- breast cancer. We conducted a cohort study of breast…”
Get full text

Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug‐induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis by Regev, Arie, Palmer, Melissa, Avigan, Mark I., Dimick‐Santos, Lara, Treem, William R., Marcinak, John F., Seekins, Daniel, Krishna, Gopal, Anania, Frank A., Freston, James W., Lewis, James H., Sanyal, Arun J., Chalasani, Naga

“…Summary Background The last decade has seen a rapid growth in the number of clinical trials enrolling patients with nonalcoholic fatty liver disease and…”
Get full text

Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development by Regev, Arie, Avigan, Mark I., Kiazand, Alexandre, Vierling, John M., Lewis, James H., Omokaro, Stephanie O., Di Bisceglie, Adrian M., Fontana, Robert J., Bonkovsky, Herbert L., Freston, James W., Uetrecht, Jack P., Miller, Ethan D., Pehlivanov, Nonko D., Haque, Syed Asif, Harrison, Melanie J., Kullak-Ublick, Gerd A., Li, Hewei, Patel, Niti N., Patwardhan, Meenal, Price, Karen D., Watkins, Paul B., Chalasani, Naga P.

“…Immune checkpoint inhibitors (ICIs) have shown significant efficacy in patients with various malignancies, however, they are associated with a wide range of…”
Get full text

Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis by Treem, William R., Palmer, Melissa, Lonjon-Domanec, Isabelle, Seekins, Daniel, Dimick-Santos, Lara, Avigan, Mark I., Marcinak, John F., Dash, Ajit, Regev, Arie, Maller, Eric, Patwardhan, Meenal, Lewis, James H., Rockey, Don C., Di Bisceglie, Adrian M., Freston, James W., Andrade, Raul J., Chalasani, Naga

“…With the widespread development of new drugs to treat chronic liver diseases (CLDs), including viral hepatitis and nonalcoholic steatohepatitis (NASH), more…”
Get full text

Clinical and Histopathologic Features of Fluoroquinolone-Induced Liver Injury by Orman, Eric S, Conjeevaram, Hari S, Vuppalanchi, Raj, Freston, James W, Rochon, James, Kleiner, David E, Hayashi, Paul H

“…Background & Aims Fluoroquinolone-induced liver injury is rare; no prospective studies of well-characterized case series have been published. We studied…”
Get full text

Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in VigiBase: Unified List Based on International Collaborative Work by Suzuki, Ayako, Andrade, Raul J., Bjornsson, Einar, Lucena, M. Isabel, Lee, William M., Yuen, Nancy A., Hunt, Christine M., Freston, James W.

“…Background: Challenges exist in the clinical diagnosis of drug-induced liver injury (DILI) and in obtaining information on hepatotoxicity in humans. Objective:…”
Get full text

Liver Safety in Patients with Type 2 Diabetes Treated with Pioglitazone: Results from a 3-Year, Randomized, Comparator-Controlled Study in the US by Tolman, Keith G., Freston, James W., Kupfer, Stuart, Perez, Alfonso

“…Background/aims: Non-alcoholic fatty liver disease (NAFLD), the major hepatic manifestation of type 2 diabetes mellitus, is the most common liver disease in…”
Get full text

Use of pH-Impedance Testing to Evaluate Patients With Suspected Extraesophageal Manifestations of Gastroesophageal Reflux Disease by Malhotra, Ashish, Freston, James W, Aziz, Khalid

“…GOALSTo report the use of pH-impedance testing in evaluating patients with suspected gastroesophageal reflux disease (GERD) with atypical symptoms…”
Get full text

Presentation of the Julius M. Friedenwald Medal to David A. Peura, MD, AGAF by Freston, James W, Yoshida, Cynthia M

Get full text

Long-Term Quality of Life Improvement in Subjects with Healed Erosive Esophagitis: Treatment with Lansoprazole by Kovacs, Thomas O, Freston, James W, Haber, Marian M, Atkinson, Stuart, Hunt, Barbara, Peura, David A

“…Background Gastroesophageal reflux disease (GERD) is a chronic symptomatic condition and may be associated with erosive esophagitis (EE). Considerable data on…”
Get full text

Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor by Freston, James W

“…Gastroesophageal reflux disease (GERD) is among the most common disorders of the gastrointestinal tract, with symptoms affecting a substantial proportion of…”
Get more information

Long-Term Efficacy of Lansoprazole in Preventing Relapse of Erosive Reflux Esophagitis by Kovacs, Thomas O, Freston, James W, Haber, Marian M, Hunt, Barbara, Atkinson, Stuart, Peura, David A

“…In a phase III study of lansoprazole treatment, patients with healed or unhealed erosive esophagitis entered a titrated open-label treatment period and…”
Get full text

Lansoprazole for Long-Term Maintenance Therapy of Erosive Esophagitis: Double-Blind Comparison with Ranitidine by Peura, David A., Freston, James W., Haber, Marian M., Kovacs, Thomas O., Hunt, Barbara, Atkinson, Stuart

“…In a study evaluating the efficacy and safety of lansoprazole to prevent the relapse of erosive esophagitis (EE), 206 of 241 patients (85%) healed after…”
Get full text

Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies by Howden, Colin W, Henning, James M, Huang, Bidan, Lukasik, Nancy, Freston, James W

“…Our objective was to compare four management strategies for heartburntherapy with an H2-receptor antagonist (ranitidine), therapy with a proton pump inhibitor…”
Get full text

Vector Analysis to Detect Hepatotoxicity Signals in Drug Development by Trost, Donald C., Freston, James W.

“…Hepatotoxicity is a leading cause of discontinuing drugs in development and withdrawing drugs from clinical use. Most withdrawals are due to idiosyncratic…”
Get full text

Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events by Freston, J W

“…New information indicates that cyclooxygenase-2 (COX-2) is constitutively expressed in several tissues, including brain, lung, pancreas, kidney, and ovary, and…”
Get more information

M1270 Correlations Between Enhanced Satiety and Reduced Calorie Intake During Intermittent Vagal Block (VBLOC Therapy) to Treat Obesity by Billington, Charles J, Kow, Lilian, Collins, Jane, Wray, Nicholas H, Tweden, Katherine S, Vollmer, Mark C, Wilson, Richard R, Yurik, Teresa M, Freston, James W, Toouli, James

Get full text

Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment by Gold, Benjamin D, Freston, James W

“…A substantial percentage of infants, children and adolescents experience gastroesophageal reflux disease (GERD) and its accompanying symptoms, as well as…”
Get full text